ZA201200980B - Treatment of brian metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent - Google Patents

Treatment of brian metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent

Info

Publication number
ZA201200980B
ZA201200980B ZA2012/00980A ZA201200980A ZA201200980B ZA 201200980 B ZA201200980 B ZA 201200980B ZA 2012/00980 A ZA2012/00980 A ZA 2012/00980A ZA 201200980 A ZA201200980 A ZA 201200980A ZA 201200980 B ZA201200980 B ZA 201200980B
Authority
ZA
South Africa
Prior art keywords
brian
metastases
inhibitors
treatment
combination
Prior art date
Application number
ZA2012/00980A
Other languages
English (en)
Inventor
Isaiah J Fidler
Sun-Jin Kim
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201200980(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of ZA201200980B publication Critical patent/ZA201200980B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
ZA2012/00980A 2009-08-10 2012-02-09 Treatment of brian metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent ZA201200980B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors

Publications (1)

Publication Number Publication Date
ZA201200980B true ZA201200980B (en) 2012-10-31

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00980A ZA201200980B (en) 2009-08-10 2012-02-09 Treatment of brian metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent

Country Status (27)

Country Link
US (2) US8999934B2 (enEXAMPLES)
EP (1) EP2464218B1 (enEXAMPLES)
JP (1) JP2013501791A (enEXAMPLES)
KR (1) KR20120088665A (enEXAMPLES)
CN (1) CN102510719B (enEXAMPLES)
AU (1) AU2010282744B2 (enEXAMPLES)
BR (1) BR112012003103A2 (enEXAMPLES)
CA (1) CA2770397A1 (enEXAMPLES)
CL (1) CL2012000333A1 (enEXAMPLES)
DK (1) DK2464218T3 (enEXAMPLES)
EA (1) EA023864B1 (enEXAMPLES)
ES (1) ES2543280T3 (enEXAMPLES)
HR (1) HRP20150890T1 (enEXAMPLES)
HU (1) HUE026005T2 (enEXAMPLES)
IL (1) IL217915A0 (enEXAMPLES)
IN (1) IN2012DN01261A (enEXAMPLES)
MA (1) MA33571B1 (enEXAMPLES)
MX (1) MX2012001562A (enEXAMPLES)
NZ (1) NZ598078A (enEXAMPLES)
PL (1) PL2464218T3 (enEXAMPLES)
PT (1) PT2464218E (enEXAMPLES)
SG (1) SG178828A1 (enEXAMPLES)
SI (1) SI2464218T1 (enEXAMPLES)
TN (1) TN2012000054A1 (enEXAMPLES)
TW (1) TWI483938B (enEXAMPLES)
WO (1) WO2011019630A2 (enEXAMPLES)
ZA (1) ZA201200980B (enEXAMPLES)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201309298A (zh) * 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CA2978679A1 (en) * 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202108194XA (en) 2015-07-13 2021-09-29 Beyondspring Pharmaceuticals Inc Plinabulin compositions
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
CN118304304A (zh) 2016-06-06 2024-07-09 大连万春布林医药有限公司 用于减少中性粒细胞减少症的组合物和方法
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
KR20190129046A (ko) 2017-02-15 2019-11-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 Nk 세포를 활성화시키기 위한 조성물 및 방법
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
WO2020233694A1 (zh) 2019-05-22 2020-11-26 石家庄智康弘仁新药开发有限公司 一种嘧啶磺酰胺类化合物的晶型及其制备方法
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431675C (en) * 2000-12-18 2011-11-08 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
HRP20120957T1 (hr) * 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid
KR20100132489A (ko) 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합
TW201309298A (zh) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物

Also Published As

Publication number Publication date
AU2010282744B2 (en) 2014-08-28
PL2464218T3 (pl) 2015-12-31
MA33571B1 (fr) 2012-09-01
SG178828A1 (en) 2012-04-27
NZ598078A (en) 2013-07-26
PT2464218E (pt) 2015-09-16
SI2464218T1 (sl) 2015-10-30
CN102510719A (zh) 2012-06-20
CN102510719B (zh) 2015-07-22
JP2013501791A (ja) 2013-01-17
EA023864B1 (ru) 2016-07-29
CL2012000333A1 (es) 2013-01-25
US20150352113A1 (en) 2015-12-10
EP2464218A2 (en) 2012-06-20
HUE026005T2 (en) 2016-04-28
EP2464218B1 (en) 2015-05-27
MX2012001562A (es) 2013-01-29
WO2011019630A3 (en) 2011-06-03
HK1171336A1 (en) 2013-03-28
BR112012003103A2 (pt) 2016-04-19
EA201270264A1 (ru) 2013-02-28
KR20120088665A (ko) 2012-08-08
TWI483938B (zh) 2015-05-11
TN2012000054A1 (en) 2013-09-19
ES2543280T3 (es) 2015-08-17
WO2011019630A2 (en) 2011-02-17
TW201109315A (en) 2011-03-16
CA2770397A1 (en) 2011-02-17
US8999934B2 (en) 2015-04-07
HRP20150890T1 (hr) 2015-09-25
IN2012DN01261A (enEXAMPLES) 2015-05-15
DK2464218T3 (en) 2015-07-20
AU2010282744A1 (en) 2012-03-22
IL217915A0 (en) 2012-03-29
US20120144510A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
ZA201200980B (en) Treatment of brian metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
ZA201405105B (en) Smoking articles and other flow delivery articles
IL218554A0 (en) Fluid delivery device
GB2547375B (en) Debris chamber with helical flow path for enhanced subterranean debris removal
ZA201105345B (en) Sustained released delivery of one or more agents
IL215608A0 (en) Drug delivery composition
IL215222A0 (en) Drug delivery device
EP2410859A4 (en) TRANSDERMAL ADMINISTRATION
IL218839A0 (en) Drug delivery device
IL215219A0 (en) Drug delivery device
IL215220A0 (en) Drug delivery device
EP2509675A4 (en) TRANSDERMAL DELIVERY SYSTEM
PL2506909T3 (pl) Urządzenie do podawania leków
IL217416A0 (en) Drug delivery delivery device
ZA201107214B (en) Delivering liquid additive
GB201020781D0 (en) Fluid delivery device
PL2515632T3 (pl) Urządzenie do podawania płynu
IL218445A0 (en) Targeted delivery using tissue-specific peptidomimetic ligands
GB201006818D0 (en) Drug delivery
IL216024A0 (en) Delivering messages using user-defined agents
IL221850A (en) Email delivery by alternative method
GB0917792D0 (en) Delivery agent
GB201121922D0 (en) Smoking articles and other flow delivery articles
GB201122470D0 (en) Moore comfy PD hose pocket
GB201100101D0 (en) Fluid loss additive for enhanced fracture clean-up